PI3K
Relay Therapeutics Advances Trials of PI3Kα, FGFR2 Inhibitors
The company is studying its PI3Kα inhibitor as a single agent and in combination with fulvestrant in patients with PI3Kα mutations in the first-in-human trial.
Regor Therapeutics to Begin US CDK2/4/6 Inhibitor Study for HR-Positive, HER2-Negative Breast Cancer
Following FDA clearance, the firm will assess its investigational agent, RGT-419B, as treatment for advanced HR-positive, HER2-negative breast cancer patients.
Kura Oncology Begins Trial of Tipifarnib, Novartis' Piqray in Head and Neck Cancer
The Phase I/II trial will enroll patients with recurrent or metastatic HRAS- or PIK3CA-dependent head and neck cancer.
SABCS Study Highlights Importance of Ranking Biomarker Evidence in Genomic Test Reports
The study showed that metastatic breast cancer patients are more likely to benefit from precision cancer drugs matched based on biomarkers with strong actionability evidence.
Breast Cancer Study Shows Number of Mutated PIK3CA Alleles Affects Tumor Aggressiveness
Studies in breast tumors revealed a "biphasic"Â relationship between mutant PIK3CA allele dosage and stem cell-like features as well as aggressiveness.